• Vladimir Khristov, Andrea Lin, Zachary Freedman, Jacob Staub, Ganesh Shenoy, Oliver Mrowczynski, Elias Rizk, Brad Zacharia, and James Connor.
• Department of Neurosurgery, Penn State Hershey College of Medicne, Hershey, Pennsylvania, USA. Electronic address: vkhristov@pennstatehealth.psu.edu.
• World Neurosurg. 2023 Feb 1; 170: 182194182-194.

AbstractThere is a pressing clinical need for minimally invasive liquid biopsies to supplement imaging in the treatment of glioblastoma. Diagnostic imaging is often difficult to interpret and the medical community is divided on distinguishing among complete response, partial response, stable disease, and progressive disease. A minimally invasive liquid biopsy would supplement imaging and clinical findings and has the capacity to be helpful in several ways: 1) diagnosis, 2) selection of patients for specific treatments, 3) tracking of treatment response, and 4) prognostic value. The liquid biome is the combination of biological fluids including blood, urine, and cerebrospinal fluid that contain small amounts of tumor cells, DNA/RNA coding material, peptides, and metabolites. Within the liquid biome, 2 broad categories of biomarkers can exist: tumor-derived, which can be directly traced to the tumor, and tumor-associated, which can be traced back to the response of the body to disease. Although tumor-associated biomarkers are promising liquid biopsy candidates, recent advances in biomarker enrichment and detection have allowed concentration on a new class of biomarker: tumor-derived biomarkers. This review focuses on making the distinction between the 2 biomarker categories and highlights promising new direction.Copyright © 2022 Elsevier Inc. All rights reserved.

12 keywords...

hide…